Long-term outcome after liver transplantation.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 22499489)

Published in Mt Sinai J Med on April 13, 2012

Authors

Kieron B L Lim1, Thomas D Schiano

Author Affiliations

1: Mount Sinai School of Medicine, New York, NY, USA.

Associated clinical trials:

EXplanted LIver and Ex-vivo Pancreatic Specimen Evaluation by 7 TESLA MRI (EXLIPSE) | NCT04012021

Articles by these authors

Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology (2006) 2.08

TIPS for refractory ascites: a 6-year single-center experience with expanded polytetrafluoroethylene-covered stent-grafts. AJR Am J Roentgenol (2015) 1.99

Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl (2008) 1.68

Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation. Am J Transplant (2003) 1.60

De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45

Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int (2013) 1.43

Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis. Eur J Gastroenterol Hepatol (2014) 1.40

A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl (2005) 1.13

Early and late outcome of cardiac surgery in patients with liver cirrhosis. Liver Transpl (2007) 1.08

Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05

Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol (2007) 1.03

Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology (2012) 1.01

Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction. Am J Gastroenterol (2002) 0.95

Outcome analysis of cirrhotic patients undergoing chest tube placement. Chest (2004) 0.94

Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant (2004) 0.91

Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl (2006) 0.90

Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant. Liver Transpl (2009) 0.90

Intranasal desmopressin versus blood transfusion in cirrhotic patients with coagulopathy undergoing dental extraction: a randomized controlled trial. J Oral Maxillofac Surg (2010) 0.88

Medication level variability index predicts rejection, possibly due to nonadherence, in adult liver transplant recipients. Liver Transpl (2014) 0.87

Hepatocellular carcinoma arising in a pigmented telangiectatic adenoma with nuclear β-catenin and glutamine synthetase positivity: case report and review of the literature. Am J Surg Pathol (2011) 0.87

Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl (2006) 0.87

Plasma cell hepatitis (de-novo autoimmune hepatitis) developing post liver transplantation. Curr Opin Organ Transplant (2012) 0.84

Obliterative portal venopathy: a clinical and histopathological review. Dig Dis Sci (2013) 0.84

Marked Differences in acute cellular rejection rates between living-donor and deceased-donor liver transplant recipients. Transplantation (2005) 0.83

Right hepatectomy for living donation: role of remnant liver volume in predicting hepatic dysfunction and complications. Surgery (2013) 0.83

Mercaptopurine-induced hepatoportal sclerosis in a patient with Crohn's disease. J Crohns Colitis (2012) 0.83

Increasing hepatic arteriole wall thickness and decreased luminal diameter occur with increasing age in normal livers. J Hepatol (2011) 0.82

Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl (2005) 0.82

Liver failure and need for liver transplantation in patients with advanced hepatoportal sclerosis. Am J Surg Pathol (2007) 0.82

Results of retransplantation for recurrent hepatitis C. Hepatology (2003) 0.82

Overdose with suicidal intent: ethical considerations for liver transplant programs. Liver Transpl (2011) 0.82

The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci (2011) 0.82

Tumors with intrahepatic bile duct differentiation in cirrhosis: implications on outcomes after liver transplantation. Transplantation (2015) 0.82

Hepatoportal sclerosis: CT and MRI appearance with histopathologic correlation. AJR Am J Roentgenol (2012) 0.81

Diagnosis of 6 mercaptopurine hepatotoxicity post liver transplantation utilizing metabolite assays. Am J Transplant (2004) 0.81

Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. Transplantation (2007) 0.79

Hemophagocytic syndrome occurring in an adult liver transplant recipient having Still's disease. Hepatol Int (2010) 0.78

Use of splenic artery embolization to relieve tense ascites following liver transplantation in a patient with paroxysmal nocturnal hemoglobinuria. Liver Transpl (2007) 0.78

Cross-genotypic polyclonal anti-HCV antibodies from human ascitic fluid. J Virol Methods (2010) 0.78

Adult live donor liver transplantation. Clin Liver Dis (2005) 0.78

An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant. Transplantation (2009) 0.78

Quantification of hepatic blood flow using a high-resolution phase-contrast MRI sequence with compressed sensing acceleration. AJR Am J Roentgenol (2015) 0.77

Acute cellular rejection resulting in sinusoidal obstruction syndrome and ascites postliver transplantation. Transplantation (2011) 0.77

Treating chronic hepatitis C in the primary care setting. Semin Liver Dis (2005) 0.77

Rapid reversal of parenteral-nutrition-associated cirrhosis following isolated intestinal transplantation. J Gastrointest Surg (2009) 0.77

Syngeneic living-donor liver transplantation without the use of immunosuppression. Gastroenterology (2002) 0.77

Domino liver transplantation: a practical option in the face of the organ shortage. Prog Transplant (2003) 0.76

Histopathology and clinical correlates of end-stage hepatitis B cirrhosis: a possible mechanism to explain the response to antiviral therapy. Liver Transpl (2005) 0.76

Hepatocellular proliferation and changes in microarchitecture of right lobe allografts in adult transplant recipients. Liver Transpl (2004) 0.76

Long-term care of the liver transplant recipient. Clin Liver Dis (2007) 0.76

Clearance of Hepatic Sphingomyelin by Olipudase Alfa Is Associated With Improvement in Lipid Profiles in Acid Sphingomyelinase Deficiency. Am J Surg Pathol (2016) 0.75

To B(iopsy) or not to B(iopsy) …. Clin Gastroenterol Hepatol (2010) 0.75

Rapidly progressive recurrent hepatitis C virus infection starting 9 days after liver transplantation. Liver Transpl (2007) 0.75

Diagnostic difficulties, therapeutic strategies, and performance of scoring systems in patients with autoimmune hepatitis and concurrent hepatitis B/C. Scand J Gastroenterol (2013) 0.75

Still disease and the liver-an underappreciated association. Gastroenterol Hepatol (N Y) (2011) 0.75

A new approach for treatment of hepatitis C in hepatitis C-autoimmune hepatitis overlap syndrome. Gastroenterol Hepatol (N Y) (2010) 0.75

Recurrence of primary biliary cirrhosis and development of autoimmune hepatitis after liver transplant: A blind histologic study. Hepatol Res (2009) 0.75

Vitamin D status of human immunodeficiency virus-positive patients with advanced liver disease enrolled in the solid organ transplantation in HIV: multi-site study. Liver Transpl (2013) 0.75

Exacerbation of sickle cell disease itself as a cause of abnormal liver chemistry tests. Dig Dis Sci (2006) 0.75

An association of myeloproliferative neoplasms and obliterative portal venopathy. Dig Dis Sci (2014) 0.75

Endoscopic diagnosis of bleeding Meckel's diverticulum in a multivisceral transplant recipient. Am J Transplant (2003) 0.75

Graft rejection occurring in post-liver transplant patients receiving cytotoxic chemotherapy: a case series. Liver Transpl (2009) 0.75

Therapeutic management of recurrent hepatitis C after liver transplantation. Liver Int (2007) 0.75

Lactulose: how many ways can one drug be prescribed? Am J Gastroenterol (2011) 0.75

Excellent results of cardiac surgery in patients with previous liver transplantation. Liver Transpl (2007) 0.75

Waitlisted Candidates With Polycystic Liver Disease are More Likely to be Transplanted Than Those With Chronic Liver Failure. Transplantation (2017) 0.75

Regression of hepatic fibrosis after intestinal transplantation in total parenteral nutrition liver disease. Clin Gastroenterol Hepatol (2008) 0.75

Recurrent hepatitis C virus infection and outcome after living-donor liver transplant. Exp Clin Transplant (2013) 0.75

Mucosal addressin cell adhesion molecule (MAdCAM-1) expression is upregulated in the cirrhotic liver and immunolocalises to the peribiliary plexus and lymphoid aggregates. Dig Dis Sci (2013) 0.75

A morphometric study of the hepatic arterioles in end-stage primary sclerosing cholangitis. Virchows Arch (2014) 0.75

Curricular guidelines for training in transplant hepatology. Liver Transpl (2002) 0.75

Increased thickness of abdominal subcutaneous adipose tissue occurs more frequently in steatohepatitis than in simple steatosis. Arch Pathol Lab Med (2013) 0.75

Serum and ascites chromogranin-A in patients with metastatic neuroendocrine tumors. Pancreas (2011) 0.75

Hepatitis C immune globulin (human) for the prevention of viral recurrence after liver transplantation. Expert Rev Clin Immunol (2007) 0.75